Skip to main content
JNJ
NYSE Life Sciences

J&J CEO Joaquin Duato Files to Sell $12.4M in Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$258.239
Mkt Cap
$620.766B
52W Low
$169.65
52W High
$274.9
52W Position info
52% above low
Off High info
6.1% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

JNJ sits 52% above its 52-week low of $169.65.

Summary

J&J CEO Joaquin Duato plans to sell 48,480 shares worth ~$12.4 million, acquired as compensation in February 2026. The sale is small relative to the company's size and follows a pattern of routine insider transactions.


Key Events · Ownership and Investor Activity · JNJ

  • CEO Files to Sell $12.4M in Stock

    Joaquin Duato, CEO and Chairman, filed a Form 144 to sell 48,480 shares with an approximate market value of $12,359,006.

  • Shares Acquired as Compensation

    The shares were acquired in February 2026 as executive compensation: 4,625 shares on 2/15/2026 and 43,855 shares on 2/13/2026.

  • Minimal Dilution Impact

    The proposed sale represents less than 0.002% of J&J's 2.41 billion outstanding shares, making it immaterial to the stock's float.

  • Part of Ongoing Insider Selling Pattern

    This is the third Form 144 filing by J&J insiders in the past 90 days, indicating routine portfolio diversification rather than a negative signal.


Analysis · JNJ · Life Sciences

CEO Joaquin Duato filed a Form 144 to sell 48,480 shares worth approximately $12.4 million. While the dollar amount is significant, it represents a tiny fraction of J&J's $621 billion market cap and less than 0.002% of outstanding shares. The sale is part of a pattern of periodic insider selling, and the shares were acquired as executive compensation earlier this year. Given Duato's dual role as CEO and Chairman, the filing draws attention, but the size relative to the company is modest and unlikely to move the stock.

At the time of this filing, JNJ was trading at $258.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $620.8B. The 52-week trading range was $169.65 to $274.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

JNJ - Latest Insights

JNJ
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
JNJ
Jul 30, 2026, 8:41 AM EDT
Source: Reuters
Importance Score:
8
JNJ
Jul 29, 2026, 8:52 PM EDT
Source: Binance News
Importance Score:
9
JNJ
Jul 29, 2026, 5:53 PM EDT
Source: Reuters
Importance Score:
8
JNJ
Jul 29, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8